Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lithuania
  Luxembourg
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tunisia
  Turkey
  Ukraine
  United Kingdom
  United States


   Infocentre

Last Update: 27-05-2014  
Related category(ies):
Health & life sciences

 

Countries involved in the project described in the article:
Denmark  |  Germany  |  Israel  |  Spain  |  Sweden  |  Switzerland  |  United Kingdom
Add to PDF "basket"

New tool in battle against Alzheimer's, Parkinson's

A more powerful mass spectrometer developed by EU-funded researchers could potentially lead to better treatments for patients with degenerative brain diseases such as Alzheimer's and Parkinson's. In recent years, mapping the human genome has led to unparalleled insight into genes – the body's blueprint.

Photo of an elderly person taking some pills

© Nenov Brothers fotolia

However, proteins, the body’s main building blocks, also play a key role in whether you're sick or healthy. In this sense proteomics – the study of proteins – is at least as important as genomics, especially since drugs work on proteins and not on genes.

Against this backdrop, a key challenge in healthcare research today revolves around advancing the field of proteomics, which in simple terms is the analysis of groups of proteins.

The EU-funded project PROSPECTS has contributed by further developing a key tool for proteomics researchers – an improved mass spectrometer which the team says has taken research to new levels. The tool is able to identify protein types by sorting their gaseous ions by mass using electric fields.

“Previously we were able to identify about half of the proteins in a given cell, but the new equipment enables us to identify almost all the proteins,” says project coordinator Dr Matthias Mann, Director at the Max Planck Institute of Biochemistry in Germany.

By using the more powerful spectrometer researchers can now document virtually all proteome processes that could lead to a specific disease. The spectrometer is produced under the trade name “Q Exactive” by industrial partner Thermo Fisher Scientific.

"You can study proteins from different angles, such as the technology required to examine proteins, and in which context we use proteomics, as well as protein coding," says Mann. "We use proteome techniques to see what's wrong with the proteomes and why they don’t function correctly in neurodegenerative diseases such as Alzheimer's and Parkinson's."

Although the project’s main goal was technical – documenting proteomes in cells much more accurately – its long-term implications are very promising, says Dr Mann.

"Understanding the proteins in a disease more accurately can pave the way for better diagnostics and eventually a more effective cure," says Mann. "Such technology can enable us to distinguish, for example, one group of cancer patients from another, rendering diagnostic applications in a clinical environment much more powerful."

Ultimately, a more accurate quantification of thousands of proteins could redefine diagnosis and therapy for many diseases, from cancer to Huntington's. And the project is also interesting commercially, with new equipment already on the market. This is positioning Europe as a pioneer in the field.

PROSPECTS brought together a multidisciplinary team of top researchers from academia and industry.

"The funding enabled partners and experts from very different scientific communities to collaborate under this multidimensional project and create outstanding synergies, which wouldn't have happened if left to their own devices," says Mann.

Even now, beyond the project's completion, some members of the consortium are still working together, he notes.

 

Project details

  • Project acronym: PROSPECTS
  • Participants:Germany (Coordinator), Switzerland, Israel, Sweden, Denmark, UK, Spain
  • Project FP7 201648
  • Total costs: € 16 688 081
  • EU contribution: € 11 777 491
  • Duration: April 2008 - March 2013

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project web site
Project information on CORDIS






  Top   Research Information Center